NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings data on Wednesday, October, 23rd. The medical research company reported $1.41 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.22 by $0.19. The medical research company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The business's revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.07 EPS. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, December, 5th. The company provided earnings per share guidance of $6.05-6.30 for the period, compared to the Thomson Reuters consensus estimate of $5.98. The company issued revenue guidance of $4.5-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

19 brokerages have issued 1-year target prices for Edwards Lifesciences' shares. Their forecasts range from $159.00 to $285.00. On average, they expect Edwards Lifesciences' stock price to reach $239.83 in the next year. This suggests that the stock has a possible downside of 0.9%. View Analyst Price Targets for Edwards Lifesciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

Media stories about EW stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,350,000 shares, an increase of 18.7% from the December 15th total of 1,980,000 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is presently 2.0 days. Currently, 1.1% of the company's shares are sold short. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Home Depot (HD), Visa (V), Walt Disney (DIS), UnitedHealth Group (UNH), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Huntington National Bank (0.15%), Chicago Capital LLC (0.07%), Birch Hill Investment Advisors LLC (0.07%), Scout Investments Inc. (0.06%), Nisa Investment Advisors LLC (0.06%) and Commerzbank Aktiengesellschaft FI (0.05%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Country Trust Bank, Gateway Investment Advisers LLC, Tributary Capital Management LLC, Assenagon Asset Management S.A., OLD National Bancorp IN, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Birch Hill Investment Advisors LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Scout Investments Inc., Commerzbank Aktiengesellschaft FI, Tuttle Tactical Management, Huntington National Bank, TrimTabs Asset Management LLC, Nisa Investment Advisors LLC and Diversified Trust Co. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $242.12.

Edwards Lifesciences has a market capitalization of $50.50 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]